$NRSN

NeuroSense Therapeutics (NRSN) filed a U.S. patent application for PrimeC to treat traumatic brain injury (TBI) and related conditions. The patent, if granted, could extend to 2047. TBI affects millions annually with no approved disease-modifying therapies. NeuroSense aims to expand PrimeC's use beyond ALS, potentially increasing its commercial value. The company is evaluating research partnerships and non-dilutive funding opportunities.

NeuroSense Therapeutics (NRSN) has scheduled a Nasdaq hearing for November 10, 2026, to appeal a delisting determination. The company has regained compliance with the minimum bid price requirement but still needs to meet the market value or equity standard. NeuroSense is targeting a New Drug Submission to Health Canada for PrimeC in December 2026 and expects a decision on non-dilutive funding for its Phase 3 trial in Q1 2027.

SpaceX (SPCX) shares rose 7.4% to $158.96 after three successful launches. CL Workshop (NWGL) fell 2.8% to $1.40 after a $200M offering. Qualcomm (QCOM) gained 0.1% to $185.04 after a 25M share offering. Pasqal (PSQL) and Neurosense (NRSN) also saw after-hours price changes.

NeuroSense (NRSN) has regained compliance with Nasdaq's minimum bid price requirement but failed to meet the $35M market value requirement. The company plans to appeal and request additional time to comply. It also announced progress in its ALS treatment, PrimeC, with a Phase 3 trial planned.

NeuroSense Therapeutics Ltd. (NRSN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 NeuroSense Provides Business Update and Progress for the First Half of 2026 CAMBRIDGE, Mass., September 25, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company focused on developing disease-

NeuroSense Therapeutics (NRSN) announced a redesigned development strategy for PrimeC in ALS, aiming to accelerate regulatory approval and reduce costs. The strategy includes AI-enabled formulation analysis, a comparative study against edaravone, and an optimized Phase 3 trial design. The company has received FDA clearance and is targeting a Canadian regulatory submission by December 2026. PrimeC is an investigational oral therapy combining ciprofloxacin and celecoxib.

NeuroSense Therapeutics (NASDAQ: NRSN) said the FDA cleared it to start the Phase 3 PARAGON study of PrimeC in ALS, targeting about 300 participants, mainly in the U.S. The company is seeking financing to fund initiation, expects to submit an NDS in Canada in Dec 2026, and plans a possible 1:4 to 1:40 reverse split to address Nasdaq bid-price issues.

NeuroSense Therapeutics (NASDAQ: NRSN) says it has completed the Pre-NDS process with Health Canada for its ALS drug PrimeC and is targeting an NDS filing in early December 2026. Health Canada aligned on submission content and structure and raised no concerns. The NDS would be supported by Phase 2b PARADIGM results, including HR 0.35 (p=0.0037) median survival benefit.

NeuroSense Therapeutics (NASDAQ: NRSN) said its Phase 2b PARADIGM trial of PrimeC in ALS met the primary endpoint: at Day 180, TDP-43 fell vs placebo (p=0.0421), with differences sustained at Day 540 (p<0.001). The company also reported slower ALSFRS-R decline and a median survival benefit (HR 0.35, p=0.004), plus no new safety signals, and said FDA clearance was obtained for Phase 3.

Ben-Noon Alon (Chief Executive Officer) purchased 250,000 shares of NeuroSense Therapeutics Ltd. (NRSN) at $0.80 ($0.20M total) on 2026-06-16.